LINC00426, a novel m 6 A-regulated long non-coding RNA, induces EMT in cervical cancer by binding to ZEB1

Siyuan Shen,Hua Jin,Xing Zhang,Yan Zhang,Xiuting Li,Wenjing Yan,Shuqian Xie,Bingjia Yu,Jing Hu,Haohan Liu,Xue Chen,Yamei Nie,Fengying Liu,Min Tang,Yun Gu,Shizhi Wang
DOI: https://doi.org/10.1016/j.cellsig.2023.110788
IF: 4.85
2023-07-01
Cellular Signalling
Abstract:Purpose To explore the function and molecular mechanism of LINC00426 in Cervical Cancer (CC), and to explore the clinical treatment strategy of LINC00426 for CC. Methods Bioinformatics analysis was used to explore the expression of LINC00426 and patient prognosis of CC. Cell function experiments were conducted to explore the potential effect of LINC00426 on CC malignant phenotypes. The difference in m 6 A modification level between the high and low expression groups of LINC00426 was analyzed by detecting the total m 6 A level. The luciferase reporter assay was used to confirm the binding of miR-200a-3p to LINC00426. The RIP assay was used to confirm the binding of LINC00426 to ZEB1. Cell viability assay was performed to detect the effect of LINC00426 on cellular drug resistance. Results LINC00426 is up-regulated in CC, which can enhance the proliferation, migration and invasion of CC cells. METTL3 promotes the expression of LINC00426 by m 6 A methylation modification. In addition, the LINC00426/miR-200a-3p/ZEB1 axis affects the proliferation, migration, and invasion of CC by regulating the expression of EMT markers. Through the detection of cell viability, we observed that overexpression LINC00426 in cells resulted in resistance to cisplatin and bleomycin, and more sensitive to imatinib. Conclusion LINC00426 is a cancer-promoting lncRNA related to m 6 A modification. The process of EMT in CC is regulated by the LINC00426/miR-200a/3p/ZEB1 axis. LINC00426 can affect the sensitivity of CC cells to chemotherapy drugs, and is expected to become a therapeutic target for CC.
cell biology
What problem does this paper attempt to address?